Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 20/20 | 1.00 |
| ▸ | TPH2 | Q8IWU9 | 11/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | CCKAR | P32238 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | MLNR | O43193 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | MC3R | P41968 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15956204 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL307901 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL1333341 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL1333338 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL19887000 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| Hydrochloric Acid SCHEMBL31105829 | 0.99 | TPH1 (0.98) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL871059 | 0.92 | TPH1 (0.85) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL2724956 | 0.92 | TPH1 (0.85) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL10185916 | 0.91 | TPH1 (0.84) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL12628142 | 0.91 | TPH1 (0.83) | TPH1TPH2ADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| EP-4739314-A1 | USE OF TRYPTOPHAN HYDROXYLASE 1 (TPH1) INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4577639-A1 | METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025008449-A1 | USE OF TRYPTOPHAN HYDROXYLASE 1 (TPH1) INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | disclosed |
| US-20240067931-A1 | METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION | TRAILHEAD BIOSYSTEMS INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024044268-A1 | METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11278549-B2 | Method of treating obesity | MCMASTER UNIVERSITY (CA) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278549-B2 | Method of treating obesity | GPR119, HTR2A, GIPR | TPH1 43/4885TPH2 25/4885ADORA3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.